Literature DB >> 25443077

Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass.

Dariush Elahi1, Panagis Galiatsatos2, Atoosa Rabiee3, Rocio Salas-Carrillo4, Amin Vakilipour5, Olga D Carlson6, Franca S Angeli5, Richard P Shannon5, Josephine M Egan6, Dana K Andersen3.   

Abstract

BACKGROUND: Bariatric surgery is the most effective treatment for the reduction of weight and resolution of type 2 diabetes mellitus (T2 DM). The objective of this study was to longitudinally assess hormonal and tissue responses after RYGB.
METHODS: Eight patients (5 with T2 DM) were studied before and after RYGB. A standardized test meal (STM) was administered before and at 1, 3, 6, 9, 12, and 15 months. Separately, a 2-hour hyperinsulinemic-euglycemic clamp (E-clamp) and a 2-hour hyperglycemic clamp (H-clamp) were performed before and at 1, 3, 6, and 12 months. Glucagon-like peptide-1 (GLP-1) was infused during the last hour of the H-clamp. Body composition was assessed with DXA methodology.
RESULTS: Enrollment body mass index was 49±3 kg/m(2) (X±SE). STM glucose and insulin responses were normalized by 3 and 6 months. GLP-1 level increased dramatically at 1, 3, and 6 months, normalizing by 12 and 15 months. Insulin sensitivity (M of E-clamp) increased progressively at 3-12 months as fat mass decreased. The insulin response to glucose alone fell progressively over 12 months but the glucose clearance/metabolism (M of H-clamp) did not change significantly until 12 months. In response to GLP-1 infusion, insulin levels fell progressively throughout the 12 months.
CONCLUSION: The early hypersecretion of GLP-1 leads to hyperinsulinemia and early normalization of glucose levels. The GLP-1 response normalizes within 1 year after surgery. Enhanced peripheral tissue sensitivity to insulin starts at 3 months and is associated with fat mass loss. β-cell sensitivity improves at 12 months and after the loss of ≈33% of excess weight. There is a tightly controlled feedback loop between peripheral tissue sensitivity and β-cell and L-cell (GLP-1) responses.
Copyright © 2014 American Society for Bariatric Surgery. All rights reserved.

Entities:  

Keywords:  Hyperglycemic clamp; Hyperinsulinemic-euglycemic clamp; RYGB; Standardized test meal; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2014        PMID: 25443077     DOI: 10.1016/j.soard.2014.07.011

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  4 in total

Review 1.  Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.

Authors:  J Grams; W Timothy Garvey
Journal:  Curr Obes Rep       Date:  2015-06

Review 2.  Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity.

Authors:  Suleman Chaudhry; Marilia Bernardes; Paul E Harris; Antonella Maffei
Journal:  Minerva Endocrinol       Date:  2015-10-27       Impact factor: 2.184

3.  The role of visceral adipose tissue on improvement in insulin sensitivity following Roux-en-Y gastric bypass: a study in Chinese diabetic patients with mild and central obesity.

Authors:  Lei Zhao; Liyong Zhu; Zhihong Su; Weizheng Li; Pengzhou Li; Yong Liu; Shengping Liu; Shaihong Zhu
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-06-29

4.  Roux-en-Y Gastric Bypass Improves Hepatic Glucose Metabolism Involving Upregulation of Sirt1 in Type 2 Diabetes Mellitus.

Authors:  Chunjie Su; Qian Cheng; Liyun Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-20       Impact factor: 3.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.